About us

Post by mgollery

 

__________________________________________________

HMMer 3 is now in beta testing! Reports are that it is more sensitive, as well as being faster. I am thinking of doing a port to Windows and/or Macintosh. What do you think?

Tahoe Informatics is an independent Bioinformatics consulting and advisory company. We will perform analyses from in-depth studies on a small protein family to creating entirely new tools for more grandiose projects.

Avoid the pain of being data-rich and information poor! Contact me at marty.gollery at gmail.com.

I have experience in
· Business development.
· Training of customers and internal personnel.
· Representation of the company through presentations and interactions with members of the press.
· Development of strategic partnerships.
· Development of new algorithms.
· Support for Sales and marketing teams.
· Customer Support.
· Quality Assurance.
· Benchmarks.
· Documentation creation and revision.
· Grant writing and Management.
· Bug tracking and software validation.

__________________________________________________

Please note that Microsoft has purchased Rosetta, and has now ceased the sale of Resolver, Syllego and Ellucidator. Support will continue for the orphan products until 2011 by an unknown third party. The software will eventually be merged with Amalga, although the details are not clear. In the meantime, try GeneSifter from Geospiza. Tell them I sent you!

__________________________________________________

The Computational challenge of today is that Sequencers are producing many times more data than they did a year ago. CPU’s, on the other hand, have not improved at the same rate. This has left an ‘analysis gap’ where people are having to triage data just to keep their heads above water.

__________________________________________________

I am now working with the good folks at Meta-Informatics to provide an informatics framework. The Life Sciences Framework (LSF) provides a metadata-driven, standards-based infrastructure for life science research. Meta-Informatics’ LSF was developed in conjunction with the Friedrich Miescher Institute, part of the Novartis Research
Foundation. The LSF supports all types of investigations including wet lab experiments, imaging, instrument-based analysis, and software-based analysis. Inputs and outputs for investigations are treated as various forms of samples including biological samples, bio-sequences, imaging and data files. The framework provides the means to track the use of samples from acquisition through disposal and all the experiments in which they are used. The LSF is an open, extensible software platform that can be used to integrate and manage a wide variety of experimental data by capturing, organizing and maintaining metadata from each experiment in a state-of-the-art software repository.

Meta-Informatics is also acting as the US agent for BioXPR. This is a great company from Belgium that has tools for metabolomics, network analysis and systems biology. Check them out at BioXPR.com and tell them Marty sent you!

 

 

Please contact me at marty.gollery at gmail.com for consultation or collaboration on the following NIH grants.

______________________________________________________________________________________

Small Businesses to Get $5M-plus in NIH Stimulus Funds

NEW YORK (GenomeWeb News) – The National Institutes of Health plans to grant at least $5 million in stimulus funding to fuel development of high-risk and high-reward biomedical research in small businesses.

Funded under the American Recovery and Reinvestment Act, the "Small Business Catalyst Awards for Accelerating Innovative Research" program will award between 20 and 25 grants of around $200,000 in fiscal 2010.

The goal is to fund projects that aim to "generate high impact results," NIH said in a funding announcement, and innovative research tools, techniques, devices, inventions, or methodologies that will improve public health, as well as create value and contribute to economic stimulus.

These "transformative" research approaches should address "major biomedical and behavioral challenges" that have the potential for commercial development, according to NIH.

NIH wants to "strongly encourage" programs that are not likely to be undertaken by academic programs or in industrial forms. The institutes also want to use the funds to encourage technologies that stem from "an emerging scientific field or technological capacity that would be beneficial if successfully commercially developed."

The program also is aimed at "promising small business concerns" that have not received previous NIH funding, and to provide them "an entrée to the NIH research portfolio," NIH said.

Applications for this funding program are due Sept. 1, with anticipated start dates in April 2010.